Related Experiment Videos
Epidermal growth factor and prostatic carcinoma: an immunohistochemical study
1Division of Urology, University of Illinois College of Medicine, Chicago 60680.
The Journal of Urology
|April 1, 1988
Summary
Epidermal growth factor (EGF) is present in most prostate cancer (CAP) tissues, especially metastatic forms. Its interaction with cancer cells may be influenced by androgen deprivation therapy, suggesting a role in prostate cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Epidermal growth factor (EGF) role in prostate cancer (CAP) is not well understood.
- EGF signaling is implicated in various cancers.
Purpose of the Study:
- To investigate the association between cytoplasmic epidermal growth factor (EGF) and different stages of prostate cancer (CAP).
- To explore the influence of androgen deprivation on EGF expression in CAP.
Main Methods:
- Indirect immunohistochemical staining of paraffin-embedded prostatic tissues.
- Analysis of tissues from benign prostatic hyperplasia (BPH), localized CAP, and metastatic CAP (untreated and treated).
Main Results:
- Cytoplasmic EGF was detected in 68% of CAP specimens, compared to 6% of BPH.
- All metastatic CAP specimens (untreated and treated) stained positive for EGF (p < 0.01).
- Increased EGF staining was observed in tumors during androgen deprivation therapy.
Conclusions:
- Prostate cancer (CAP) cells exhibit epidermal growth factor (EGF).
- EGF presence is significantly higher in metastatic CAP.
- Androgenic status may modulate the interaction between EGF and prostate cancer cells.